Thomas Eldered
Executive Chairman @ Flerie Invest
Jordbro, Sweden
Thomas Eldered is a Series A investor at Flerie Invest in Jordbro focused on Pharmaceutical and Medical. Thomas Eldered - Executive Chairman @ Flerie Invest
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Thomas Eldered invests in
Stages Thomas Eldered invests in
Countries Thomas Eldered invests in
Investment Focus
Industry
- Pharmaceutical 2 (33%)
- Medical 1 (17%)
- Biotechnology 1 (17%)
Stage
- Series A 1 (17%)
- Series B 1 (17%)
- Corporate Round 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- Israel 1 (17%)
- Germany 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
KAHR medical
|
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $22M / Series B / Oct 15, 2025 | |
Coriolis Pharma
|
Coriolis Pharma is a globally operating independent service provider for research and development of biopharmaceutical drugs. | Corporate Round / Oct 16, 2023 | |
|
KAHR medical
|
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M / Venture - Series Unknown / Jun 16, 2021 | |
|
KAHR medical
|
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $18M / Venture - Series Unknown / Feb 25, 2020 | |
|
KAHR medical
|
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $12M / Series B / Dec 01, 2015 | |
|
KAHR medical
|
KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $2.5M / Series A / Sep 01, 2013 |
Co-Investors
About Flerie Invest
Flerie Invest is a Europian investment firm that makes investments in the health care sector companies.
Flerie Invest Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Thomas Eldered
Executive Chairman
|
|||
Ted Fjällman
Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Thomas Eldered invest in?
Thomas Eldered invests primarily in Pharmaceutical, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Thomas Eldered last invest?
The most recent investment recorded for Thomas Eldered closed in Oct 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
